Major depressive disorder, anhedonia and agomelatine: An open-label study

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 1, 2011, Pages 109-114

  Di Giannantonio, Massimo ^a   Di Iorio, G ^a   Guglielmo, R ^b   De Berardis, D ^a,c   Conti, C M ^a   Acciavatti, T ^a   Cornelio, M ^a   Martinotti, G ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Casa di Cura Neuropsichiatrica Villa Maria Pia   (Italy)

^c ASL Teramo   (Italy)

Author keywords

Agomelatine; Anhedonia; Antidepressant; Major depressant disorder (MDD); Sleep disturbance

Indexed keywords

AGOMELATINE; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2C RECEPTOR;

ADULT; ANHEDONIA; ARTICLE; CLINICAL ARTICLE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; LEEDS SLEEP EVALUATION QUESTIONNAIRE; MAJOR DEPRESSION; MALE; NAUSEA; QUESTIONNAIRE; SIDE EFFECT; SLEEP QUALITY; SNAITH HAMILTON RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; CLINICAL TRIAL; DRUG POTENTIATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ACETAMIDES; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 79955669643     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Carta MG, Aguglia E, Caraci A, et al. The use of antidepressant drugs and the lifetime prevalence of major depressive disorders in Italy. Clin Pract Epidemiol Mental Health, 2010; 6:94-100.
2. World Health Organization. The Global burden of disease: 2004 update. World Health Organization, Geneva, 2008; p.43-51.
3. Spijker J, Bijl RV, de Graaf R, Nolen WA. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 2001; 103: 122-30. (Pubitemid 32147133)
4. Taylor DJ, Walters HM, Vittengl JR, Krebaum S, Jarrett RB. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J Affect Disord 2010; 123:181-7.
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps. Am J Psychiatry 2006; 163:1905-17. (Pubitemid 44807782)
6. Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008; 42:1822-31.
7. Yours S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, Lesieur D, Guardiola-Lemaitre B. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992; 35:1484-6.
8. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28:694-703.
9. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110:135-370.
10. Bourin M, Mocae E, Porsolt R. Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29:126-33. (Pubitemid 38570217)
11. Bertaina-Anglade V, Mocaer E, Drieu La Rochelle C. Antidepressant-like action of S20098 (agomelatine) in the learned helplessness test. Int J Neuropsychopharmacology 2002; 5(S):65.
12. Loo, H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17:239-47.
13. Kennedy S.H, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16:93-100. (Pubitemid 43145814)
14. Olie, JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10:661-73. (Pubitemid 47517525)
15. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010; 30:135-44.
16. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010; 71:616-26.
17. Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006; 21(S):31-35.
18. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double blind, placebo controlled discontinuation study. Int Clin Psychopharmacol 2004; 19:271-80. (Pubitemid 39141943)
19. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006; 21(S):25-29.
20. Kupfer DJ. Depression and associated sleep disturbances: patient benefit with agomelatine. Eur Neuropsychopharmacol 2006; 16(S):639-43.
21. De Berardis D, Di Iorio G, Acciavatti T, et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurological Disorders Drug Targets 2011; 10:119-32.
22. Molin J, Mellerup E, Bolwig T, Scheike T, Dam H. The influence of climate on development of winter depression. J Affect Disord 1996; 37:151-5. (Pubitemid 26126298)
23. Magnusson A. An overview of epidemiological studies on seasonal affective disorder. Acta Psychiatr Scand 2000; 101:176-84. (Pubitemid 30108368)
24. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:561-6.
25. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68:1723-32. (Pubitemid 350247502)
26. Farina B, Delia Marca G, Mennuni G, Mazza S, De Risio S, Di Giannantonio M. The effects of reboxetine on human sleep architecture in depression: preliminary results. J Affect Disord 2002; 71:273-5.
27. Ribot T. La Psychologie Des Sentiments. Felix Alcan, Paris, 1896.
28. Loas G, Pierson A. Anhedonia in psychiatry: a review. Ann Med Psychol (Paris) 1989; 147:705-17.
29. Costello CG. Depression: Loss of reinforcers or loss of reinforcer effectiveness? Behavior Therapy 1972; 3:240-47.
30. Meehl PE. Hedonic capacity: some conjectures. Bull Menninger Clin 1975; 39:295-307.
31. Martinotti G, Cloninger CR, Janiri L. Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. American J Drug Alcohol Abuse 2008; 34:177-83. (Pubitemid 351302171)
32. Janiri L, Martinotti G, Dario T, Reina D, Paparello F, Pozzi G, Addolorato G, Di Giannantonio M, De Risio S. Anhedonia and substance-related symptoms in detoxified drug dependent subjects: a correlation study. Neuropsychobiology 2005; 52:37-44. (Pubitemid 40910948)
33. Dryman A, Eaton WW. Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1991; 84:1-5.
34. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 2005; 58:843-53. (Pubitemid 41790711)